ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.69 USD
+0.33 (2.02%)
Updated Sep 4, 2024 04:00 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Income Statements
Fiscal Year end for ACADIA Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 726 | 517 | 484 | 442 | 339 |
Cost Of Goods | 42 | 10 | 11 | 10 | 11 |
Gross Profit | 685 | 507 | 473 | 432 | 328 |
Selling & Adminstrative & Depr. & Amort Expenses | 758 | 731 | 644 | 718 | 574 |
Income After Depreciation & Amortization | -73 | -224 | -170 | -287 | -247 |
Non-Operating Income | 22 | 10 | 3 | 6 | 12 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -51 | -213 | -168 | -281 | -234 |
Income Taxes | 10 | 3 | 0 | 1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -61 | -216 | -168 | -282 | -235 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -61 | -216 | -168 | -282 | -235 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -224 | -165 | -282 | -247 |
Depreciation & Amortization (Cash Flow) | -2 | -1 | 6 | 4 | -1 |
Income After Depreciation & Amortization | -73 | -224 | -170 | -287 | -247 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 163.82 | 161.68 | 160.49 | 157.33 | 147.20 |
Diluted EPS Before Non-Recurring Items | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 |
Diluted Net EPS (GAAP) | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 |
Fiscal Year end for ACADIA Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 241.96 | 205.83 | 231.04 | 211.70 | 165.24 |
Cost Of Goods | 18.23 | 22.95 | 17.89 | 14.62 | 7.46 |
Gross Profit | 223.73 | 182.88 | 213.15 | 197.08 | 157.78 |
SG&A, R&D, and Dept/Amort Expenses | 193.29 | 167.67 | 178.21 | 254.85 | 154.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 30.44 | 15.21 | 34.94 | -57.77 | 3.04 |
Non-Operating Income | 6.75 | 5.79 | 4.76 | 5.63 | 3.31 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 37.18 | 21.00 | 39.70 | -52.14 | 6.34 |
Income Taxes | 3.79 | 4.45 | -6.09 | 13.03 | 5.23 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 33.39 | 16.56 | 45.80 | -65.18 | 1.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 33.39 | 16.56 | 45.80 | -65.18 | 1.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 166.17 | 166.62 | 166.51 | 164.23 | 165.05 |
Diluted EPS Before Non-Recurring Items | 0.20 | 0.10 | 0.28 | -0.40 | 0.01 |
Diluted Net EPS (GAAP) | 0.20 | 0.10 | 0.29 | -0.40 | 0.01 |